Breast cancer remains a significant health challenge, with one in eight women diagnosed in their lifetime. Despite advancements in detection and treatment, a cure is still elusive, making the development of a vaccine by Anixa Biosciences a promising breakthrough. This early-stage vaccine aims to prevent breast cancer by training the immune system to target specific cells associated with the disease.
The vaccine involves a series of three injections and is currently in phase 1 clinical trials, focusing on women with triple-negative breast cancer. Initial results show a positive immune response in 75% of participants, but challenges remain, including the need for a larger and more diverse participant pool. The ultimate goal is to make this vaccine available to all women, potentially transforming the landscape of cancer treatment.
• Anixa Biosciences develops a vaccine to prevent breast cancer.
• The vaccine targets specific cells to train the immune system.
The vaccine is currently in phase 1 clinical trials to assess its safety and efficacy.
The vaccine aims to elicit a robust immune response to prevent cancerous cells from developing.
The vaccine targets a lactation protein antigen that appears during childbirth and breast cancer.
Anixa Biosciences is working on a vaccine aimed at preventing breast cancer before it starts.
english.mathrubhumi 10month
FOX News on MSN.com 8month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.